# 2025-08855: FDA Patent Clock Starts Ticking for ELAHERE's Review Period

2025-08855, Determination of Regulatory Review Period for Purposes of Patent Extension; ELAHERE, is a Federal Register notice from Health and Human Services Department, Food and Drug Administration published 2025-05-19, effective Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by July 18, 2025. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by November 17, 2025.; PRIA reads it as touching household money (as of 2026-10-21).

- Canonical: https://policyrisk.com/federal-register/2025-08855
- As of: 2026-10-21
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-08855
- Title: Determination of Regulatory Review Period for Purposes of Patent Extension; ELAHERE
- Type: Notice
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 21311
- Published: 2025-05-19
- Effective: Anyone with knowledge that any of the dates as published (see SUPPLEMENTARY INFORMATION) are incorrect must submit either electronic or written comments and ask for a redetermination by July 18, 2025. Furthermore, any interested person may petition FDA for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period by November 17, 2025.
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-10-21

## In one line

FDA Patent Clock Starts Ticking for ELAHERE's Review Period

## Summary

The FDA has officially set the review period for ELAHERE, a human biological product, which helps decide if its patent can be extended. This affects the company behind ELAHERE and anyone interested in patent timing or drug development. If you think the dates are wrong or want to challenge the applicant’s effort during review, you’ve got until mid-2025 to speak up—so don’t miss your chance!

## Abstract

The Food and Drug Administration (FDA or the Agency) has determined the regulatory review period for ELAHERE and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for the extension of a patent which claims that human biological product.

## Effects PRIA read

- Regulatory review period set at 3,867 days: benefit, high. FDA determined the regulatory review period for ELAHERE is 3,867 days in total: 3,635 days for the testing phase and 232 days for the approval phase. FDA verified the key dates used: IND effective April 15, 2012; BLA initially submitted March 28, 2022; BLA approved November 14, 2022.
- Applicant's requested patent extension lengths: benefit, high. ImmunoGen, Inc. submitted patent term restoration applications for ELAHERE and in those applications seeks patent term extensions of 1,149 days; 1,677 days; 1,733 days; 1,740 days; or 1,775 days. FDA notes that the USPTO will apply statutory limitations when calculating the actual extension.
- Opportunity to challenge dates and due diligence: benefit, low. Anyone who believes the published dates are incorrect may submit comments and ask for a redetermination by July 18, 2025, and any interested person may petition FDA about whether the applicant acted with due diligence by November 17, 2025. The notice specifies how to submit comments and petitions e…
- ELAHere approved under accelerated approval: benefit, high. FDA approved ELAHERE (mirvetuximab soravtansine-gynx) for adult patients with folate receptor alpha (FRα)–positive, platinum‑resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens. The approval (granted November 14…

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-08855 on federalregister.gov](https://www.federalregister.gov/documents/2025/05/19/2025-08855/determination-of-regulatory-review-period-for-purposes-of-patent-extension-elahere)
- [2025-08855 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-05-19/pdf/2025-08855.pdf)

## Related
- [Previous: 2025-08852, Self-Regulatory Organizations; NYSE Texas, Inc.; Notice of Filing and Immediate…](https://policyrisk.com/federal-register/2025-08852)
- [Next: 2025-08856, Colorado River Basin Salinity Control Advisory Council Notice of Public Meeting](https://policyrisk.com/federal-register/2025-08856)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-08855 (as of 2026-10-21).
